Endothelial GDF15 deficiency enhances barrier function and mitigates pulmonary fibrosis

Authors:

Abstract
Pulmonary fibrosis is frequently accompanied by pulmonary hypertension, which can occur disproportionate to the extent of fibrosis, suggesting a fibrosis-independent vascular remodeling process. Here, we demonstrated that plasma growth differentiation factor 15 (GDF15) is elevated across diverse fibrotic lung disease subtypes and correlates with markers of elevated right heart pressures but not pulmonary function indices, indicating a possible link to endothelial cell dysfunction. To investigate the import of endothelial GDF15 as a modifier of lung fibrosis pathogenesis, we generated endothelial cell–specific Gdf15 -KO mice, which showed protection from bleomycin-induced lung injury and fibrosis, with preserved lung function. RNA-seq of human pulmonary microvascular endothelial cells revealed altered expression of barrier-regulatory genes in GDF15 -deficient endothelial cells compared with controls. Functional studies confirmed that GDF15 knockdown attenuates thrombin-induced barrier disruption by reducing cytosolic Ca 2+ responses. Together, these findings implicate endothelial GDF15 as a modifier of vascular permeability and Ca 2+ signaling and a contributor to lung injury and fibrosis.
Funding Information
  • National Institutes of Health (5T32HL007563)
  • National Institutes of Health (R01HL172493)
  • National Institutes of Health (R35HL161177)
  • National Institutes of Health (P50AR080612)

This publication has 64 references indexed in Scilit: